Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 68

1.

Intracoronary pharmacotherapy in the management of coronary microvascular dysfunction.

Kunadian V, Zorkun C, Williams SP, Biller LH, Palmer AM, Ogando KJ, Lew ME, Nethala N, Gibson WJ, Marble SJ, Buros JL, Gibson CM.

J Thromb Thrombolysis. 2008 Dec;26(3):234-42. doi: 10.1007/s11239-008-0276-0. Review.

PMID:
18818881
2.

The no-reflow phenomenon in the coronary circulation.

Kiernan TJ, Ruggiero NJ 2nd, Bernal JM, Don CW, Witzke C, Kiernan GD, Cubeddu RJ, Yan BP.

Cardiovasc Hematol Agents Med Chem. 2009 Jul;7(3):181-92. Review.

PMID:
19689256
3.

Intracoronary injection of drugs to treat no--reflow phenomenon and microcirculatory dysfunction.

Rognoni A, Lupi A, Cavallino C, Secco GG, Rosso R, Bongo AS.

Cardiovasc Hematol Agents Med Chem. 2013 Jun;11(2):84-8. Review.

PMID:
22973862
4.

Pharmacological approach of no-reflow phenomenon related with percutaneous coronary interventions.

Valero SJ, Moreno R, Reyes RM, Recalde AS, Galeote G, Calvo L, Villate A, Sendón JL.

Cardiovasc Hematol Agents Med Chem. 2008 Apr;6(2):125-9. Review.

PMID:
18473777
5.

Update in pharmacological management of coronary no-reflow phenomenon.

Salinas P, Jimenez-Valero S, Moreno R, Sanchez-Recalde A, Galeote G, Calvo L, Ruiz-Garcia J, Carrizo S, Trucco G, Lopez-Sendon J.

Cardiovasc Hematol Agents Med Chem. 2012 Sep;10(3):256-64. Review.

PMID:
22827250
6.

Peri-interventional coronary vasomotion.

Gregorini L, Marco J, Heusch G.

J Mol Cell Cardiol. 2012 Apr;52(4):883-9. doi: 10.1016/j.yjmcc.2011.09.017. Review.

PMID:
21971073
7.

Management of 'no-reflow' complicating reperfusion therapy.

Lee KW, Norell MS.

Acute Card Care. 2008;10(1):5-14. doi: 10.1080/17482940701744318. Review.

PMID:
18449813
8.

Coronary no-reflow phenomenon: from the experimental laboratory to the cardiac catheterization laboratory.

Rezkalla SH, Kloner RA.

Catheter Cardiovasc Interv. 2008 Dec 1;72(7):950-7. doi: 10.1002/ccd.21715. Review.

PMID:
19021281
9.

Randomized evaluation of intracoronary nitroprusside vs. adenosine after thrombus aspiration during primary percutaneous coronary intervention for the prevention of no-reflow in acute myocardial infarction: the REOPEN-AMI study protocol.

Niccoli G, D'amario D, Spaziani C, Cosentino N, Marino M, Rigattieri S, Schiavo PL, De Vita MR, Tarantino F, Bartorelli A, Fabbiocchi F, Prati F, Imola F, Valgimigli M, Ferrari R, Crea F.

J Cardiovasc Med (Hagerstown). 2009 Jul;10(7):585-92. doi: 10.2459/JCM.0b013e32832b3571.

PMID:
19384242
10.

Adjunctive thrombectomy and distal protection in primary percutaneous coronary intervention: impact on microvascular perfusion and outcomes.

Srinivasan M, Rihal C, Holmes DR, Prasad A.

Circulation. 2009 Mar 10;119(9):1311-9. doi: 10.1161/CIRCULATIONAHA.108.831453. Review.

11.

Coronary microvascular reperfusion injury and no-reflow in acute myocardial infarction.

Kang S, Yang Y.

Clin Invest Med. 2007;30(3):E133-45. Review.

PMID:
17716552
12.

Pathophysiology of the no-reflow phenomenon.

Vrints CJ.

Acute Card Care. 2009;11(2):69-76. doi: 10.1080/17482940902978061. Review.

PMID:
19526383
13.

Lipid-rich plaque and myocardial perfusion after successful stenting in patients with non-ST-segment elevation acute coronary syndrome: an optical coherence tomography study.

Tanaka A, Imanishi T, Kitabata H, Kubo T, Takarada S, Tanimoto T, Kuroi A, Tsujioka H, Ikejima H, Komukai K, Kataiwa H, Okouchi K, Kashiwaghi M, Ishibashi K, Matsumoto H, Takemoto K, Nakamura N, Hirata K, Mizukoshi M, Akasaka T.

Eur Heart J. 2009 Jun;30(11):1348-55. doi: 10.1093/eurheartj/ehp122.

14.

Pharmaceutical interventions for the management of no-reflow.

Fischell TA.

J Invasive Cardiol. 2008 Jul;20(7):374-9. Review.

15.

[Role of leucocytes in microvascular malperfusion in reperfused acute myocardial infarction].

Sezer M, Umman S.

Anadolu Kardiyol Derg. 2008 Feb;8(1):48-50. Review. Turkish.

16.

Intensive cholesterol lowering with statin improves the outcomes of percutaneous coronary intervention in patients with acute coronary syndrome.

Jia XW, Fu XH, Zhang J, Gu XS, Fan WZ, Wu WL, Hao GZ, Li SQ, Jiang YF.

Chin Med J (Engl). 2009 Mar 20;122(6):659-64.

PMID:
19323930
17.

Coronary microembolization: from bedside to bench and back to bedside.

Heusch G, Kleinbongard P, Böse D, Levkau B, Haude M, Schulz R, Erbel R.

Circulation. 2009 Nov 3;120(18):1822-36. doi: 10.1161/CIRCULATIONAHA.109.888784. Review.

18.

Prasugrel in acute coronary syndrome patients undergoing percutaneous coronary intervention.

Capranzano P, Ferreiro JL, Angiolillo DJ.

Expert Rev Cardiovasc Ther. 2009 Apr;7(4):361-9. doi: 10.1586/erc.09.4. Review.

PMID:
19379060
19.

The no-reflow phenomenon in coronary arteries.

Kelly RV, Cohen MG, Runge MS, Stouffer GA.

J Thromb Haemost. 2004 Nov;2(11):1903-7. Review.

20.

Prevention of no flow/slow reflow phenomenon in primary PCI by Nicorandil.

J E, Juneja MS, George T, Sr R, V V, Ak B, Kalyani S, Pandurangi UM, Latchumanadhas K, S MA.

Indian Heart J. 2007 May-Jun;59(3):246-9.

PMID:
19124934
Items per page

Supplemental Content

Support Center